Pub Date : 2026-04-11DOI: 10.1016/j.oret.2026.03.008
Maxwell J Prenner, Eric Nudleman
{"title":"Re: Zhang et al.: Rates of endophthalmitis in prefilled versus nonprefilled syringes for intravitreal injections: a systematic review and meta-analysis. (Ophthalmology Retina. 2026;10:165-175).","authors":"Maxwell J Prenner, Eric Nudleman","doi":"10.1016/j.oret.2026.03.008","DOIUrl":"https://doi.org/10.1016/j.oret.2026.03.008","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-10DOI: 10.1016/j.oret.2026.03.009
Charles Zhang, Daniel A Lai, Georges AbouKasm, Sinan Ersan, Nicholas Leung, Daniel Zhu, Nimesh A Patel, Harry W Flynn, Nicolas A Yannuzzi
{"title":"Reply.","authors":"Charles Zhang, Daniel A Lai, Georges AbouKasm, Sinan Ersan, Nicholas Leung, Daniel Zhu, Nimesh A Patel, Harry W Flynn, Nicolas A Yannuzzi","doi":"10.1016/j.oret.2026.03.009","DOIUrl":"https://doi.org/10.1016/j.oret.2026.03.009","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-10DOI: 10.1016/j.oret.2026.04.004
Laure Canizares, Youssef Abdelmassih, Thibaut Chapron, Ismael Chehaibou, Yannick Le Mer, Sebastien Bruneau, Florence Metge, Aude Couturier, Georges Caputo
Purpose: To estimate the incidence of full-thickness macular hole (FTMH) bilateralization, identify risk factors for development in the fellow eye, and compare surgical outcomes between first and second eyes.
Design: Retrospective consecutive case series.
Participants: Patients with unilateral idiopathic FTMH.
Methods: Clinical records and SD-OCT were reviewed to assess FTMH characteristics, bilateralization, and vitreoretinal interface status in the fellow eye, including posterior vitreous detachment (PVD), vitreomacular traction (VMT), epiretinal membrane, and lamellar hole.
Main outcome measures: Incidence of fellow-eye FTMH, time to bilateralization, risk factors, and surgical outcomes.
Results: Among 576 patients (mean age, 67.2 ± 8.7 years), 34 (5.9%) developed a fellow-eye FTMH over a mean follow-up of 27.3 ± 25.3 months. The cumulative incidence was 4 ± 1% at 1 year and 12 ± 2% at 5 years. Eyes with VMT had a markedly higher risk, reaching 19 ± 6% at 1 year and 27 ± 7% at 2 years, and developed FTMH earlier than eyes without VMT. In multivariable analysis, VMT was the strongest independent predictor of bilateralization (odds ratio, 12.9; 95% CI, 3.5-47.2; P < 0.001). Axial length and high myopia were not associated with fellow-eye FTMH. Fellow-eye holes were smaller and had better visual acuity at diagnosis, but final visual acuity and closure rates were comparable to first eyes.
Conclusions: Fellow-eye FTMH occurs in approximately 12% of patients at 5 years. VMT and absence of PVD are the principal risk factors, whereas high myopia does not increase bilateralization risk. Close surveillance is warranted, particularly within the first 2 years in eyes with VMT.
目的：评估全层黄斑裂孔（FTMH）双侧化的发生率，确定同侧眼发展的危险因素，并比较第一眼和第二眼的手术结果。设计：回顾性连续病例系列。参与者：单侧特发性FTMH患者。方法：回顾临床记录和SD-OCT，评估FTMH特征、双侧化和同侧眼玻璃体视网膜界面状态，包括玻璃体后脱离（PVD）、玻璃体黄斑牵引（VMT）、视网膜前膜和板层孔。主要观察指标：同眼FTMH发生率、双侧化时间、危险因素和手术结果。结果：576例患者（平均年龄67.2±8.7岁）中，34例（5.9%）在平均27.3±25.3个月的随访期间发生了同眼FTMH。累积发病率为1年（4±1%），5年（12±2%）。有VMT的眼睛发生FTMH的风险明显高于无VMT的眼睛，1年为19.6%，2年为27.7%，发生FTMH的时间比无VMT的眼睛早。在多变量分析中，VMT是双侧化最强的独立预测因子（优势比12.9;95% CI, 3.5-47.2; P < 0.001）。眼轴长度和高度近视与同眼FTMH无关。同眼孔较小，诊断时视力较好，但最终视力和闭合率与第一只眼相当。结论：约12%的患者在5年时发生同眼FTMH。VMT和无PVD是主要的危险因素，而高度近视不增加双侧化风险。密切监视是必要的，特别是在头2年的眼睛与VMT。
{"title":"Incidence and risk factors of full-thickness macular hole in fellow eyes.","authors":"Laure Canizares, Youssef Abdelmassih, Thibaut Chapron, Ismael Chehaibou, Yannick Le Mer, Sebastien Bruneau, Florence Metge, Aude Couturier, Georges Caputo","doi":"10.1016/j.oret.2026.04.004","DOIUrl":"https://doi.org/10.1016/j.oret.2026.04.004","url":null,"abstract":"<p><strong>Purpose: </strong>To estimate the incidence of full-thickness macular hole (FTMH) bilateralization, identify risk factors for development in the fellow eye, and compare surgical outcomes between first and second eyes.</p><p><strong>Design: </strong>Retrospective consecutive case series.</p><p><strong>Participants: </strong>Patients with unilateral idiopathic FTMH.</p><p><strong>Methods: </strong>Clinical records and SD-OCT were reviewed to assess FTMH characteristics, bilateralization, and vitreoretinal interface status in the fellow eye, including posterior vitreous detachment (PVD), vitreomacular traction (VMT), epiretinal membrane, and lamellar hole.</p><p><strong>Main outcome measures: </strong>Incidence of fellow-eye FTMH, time to bilateralization, risk factors, and surgical outcomes.</p><p><strong>Results: </strong>Among 576 patients (mean age, 67.2 ± 8.7 years), 34 (5.9%) developed a fellow-eye FTMH over a mean follow-up of 27.3 ± 25.3 months. The cumulative incidence was 4 ± 1% at 1 year and 12 ± 2% at 5 years. Eyes with VMT had a markedly higher risk, reaching 19 ± 6% at 1 year and 27 ± 7% at 2 years, and developed FTMH earlier than eyes without VMT. In multivariable analysis, VMT was the strongest independent predictor of bilateralization (odds ratio, 12.9; 95% CI, 3.5-47.2; P < 0.001). Axial length and high myopia were not associated with fellow-eye FTMH. Fellow-eye holes were smaller and had better visual acuity at diagnosis, but final visual acuity and closure rates were comparable to first eyes.</p><p><strong>Conclusions: </strong>Fellow-eye FTMH occurs in approximately 12% of patients at 5 years. VMT and absence of PVD are the principal risk factors, whereas high myopia does not increase bilateralization risk. Close surveillance is warranted, particularly within the first 2 years in eyes with VMT.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-06DOI: 10.1016/j.oret.2026.03.023
Srujay Pandiri, Celine Chaaya, Arthur Brant, Sandra Hoyek, Romy Bejjani, Davina A Malek, Yan Zhao, Grace Baldwin, Caroline Awh, Nimesh A Patel
Topic: The purpose of this study is to report the sensitivities and specificities of telemedicine technology used to screen for referral-warranted (RW)-ROP and treatment-required (TR)-ROP.
Clinical relevance: Retinopathy of Prematurity (ROP) is a leading cause of blindness in premature infants. Tele-ROP has emerged as a novel method to help screen for ROP in low-resource locations and showcases significant promise.
Methods: PubMed, Embase, and Web of Science databases were searched from 01/2000 to 10/2024. Studies reporting sensitivities and specificities of RW-ROP or TR-ROP were included in the meta-analysis. These values were combined using random-effects meta-analysis. Risk of bias was determined via the Newcastle Ottawa Scale and Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. The study protocol was registered and published on the International Prospective Register of Systematic Reviews (CRD42024608378).
Results: Of 905 identified studies, 16 studies met inclusion criteria, and were thus included in the meta-analysis.6,149 eyes of 3,527 patients were studied. The sensitivity in the RW group was 0.93 [95% CI, 0.83-0.98], with low heterogeneity between studies (I2 = 0.0%; p = 0.75), and the overall specificity was 0.95 [95% CI, 0.85-0.98], with heterogeneity between studies (I2 = 91.2%; p < 0.001). Certainty of evidence was graded as moderate for sensitivity and high for specificity using the GRADE approach. Regarding the TR-ROP group, the sensitivity was 0.97 [95% CI, 0.92-0.99], with low heterogeneity between studies (I2 = 0.0%; p = 0.97), and the specificity was 0.97 [95% CI, 0.91-0.99], with heterogeneity between studies (I2 = 88.2%; p < 0.001). Certainty of evidence was graded as high Post-2010 studies had greater sensitivities and specificities for RW-ROP: p < 0.001 and p = 0.77, respectively. TR-ROP sensitivity and specificity were higher in studies conducted after 2010 compared to prior: p = 0.06 and p < 0.001, respectively. Sensitivity and specificity for US vs non-US based studies were (0.83 vs 0.92, p = 0.012) and (0.97 vs 0.88, p = 0.04), respectively. Specificity for TR-ROP between US vs non-US based studies were 0.98 vs 0.95, p < 0.001, respectively.
Conclusion: Remote digital fundus imaging may be an option for retinopathy of prematurity screening, particularly in low-resource areas. There was significant variability. This suggests a need for continued formal training for both photographers and graders.
主题：本研究的目的是报告用于筛查转诊保证(RW)-ROP和治疗要求(TR)-ROP的远程医疗技术的敏感性和特异性。临床相关性：早产儿视网膜病变（ROP）是早产儿失明的主要原因。远程机械钻速已经成为一种帮助在低资源地区筛选机械钻速的新方法，并显示出巨大的前景。方法：检索2000年1月~ 2024年10月PubMed、Embase和Web of Science数据库。报告RW-ROP或TR-ROP敏感性和特异性的研究被纳入meta分析。使用随机效应荟萃分析合并这些值。偏倚风险通过纽卡斯尔渥太华量表和诊断准确性研究质量评估-2 （QUADAS-2）工具确定。该研究方案已在国际前瞻性系统评价登记册（CRD42024608378）上注册并发表。结果：在905项确定的研究中，16项研究符合纳入标准，因此被纳入meta分析。对3527名患者的6149只眼睛进行了研究。RW组的敏感性为0.93 [95% CI, 0.83-0.98]，研究间异质性较低（I2 = 0.0%, p = 0.75），总特异性为0.95 [95% CI, 0.85-0.98]，研究间异质性较低（I2 = 91.2%, p < 0.001）。使用GRADE方法，证据的确定性被分级为中度敏感性和高特异性。TR-ROP组的敏感性为0.97 [95% CI, 0.92-0.99]，研究间异质性较低（I2 = 0.0%, p = 0.97），特异性为0.97 [95% CI, 0.91-0.99]，研究间异质性较低（I2 = 88.2%, p < 0.001）。证据确定性评级为高：2010年后研究对RW-ROP具有更高的敏感性和特异性：分别为p < 0.001和p = 0.77。2010年以后进行的研究中，TR-ROP的敏感性和特异性均高于之前的研究：p = 0.06和p < 0.001。美国和非美国研究的敏感性和特异性分别为（0.83 vs 0.92, p = 0.012）和（0.97 vs 0.88, p = 0.04）。美国和非美国研究中TR-ROP的特异性分别为0.98和0.95,p < 0.001。结论：远程数字眼底成像可能是早产儿视网膜病变筛查的一种选择，特别是在资源匮乏的地区。有显著的可变性。这表明摄影师和评分员都需要继续接受正规培训。
{"title":"Telemedicine Utilization for Retinopathy of Prematurity Screening in Premature Infants: Systematic Review and Meta-analysis.","authors":"Srujay Pandiri, Celine Chaaya, Arthur Brant, Sandra Hoyek, Romy Bejjani, Davina A Malek, Yan Zhao, Grace Baldwin, Caroline Awh, Nimesh A Patel","doi":"10.1016/j.oret.2026.03.023","DOIUrl":"https://doi.org/10.1016/j.oret.2026.03.023","url":null,"abstract":"<p><strong>Topic: </strong>The purpose of this study is to report the sensitivities and specificities of telemedicine technology used to screen for referral-warranted (RW)-ROP and treatment-required (TR)-ROP.</p><p><strong>Clinical relevance: </strong>Retinopathy of Prematurity (ROP) is a leading cause of blindness in premature infants. Tele-ROP has emerged as a novel method to help screen for ROP in low-resource locations and showcases significant promise.</p><p><strong>Methods: </strong>PubMed, Embase, and Web of Science databases were searched from 01/2000 to 10/2024. Studies reporting sensitivities and specificities of RW-ROP or TR-ROP were included in the meta-analysis. These values were combined using random-effects meta-analysis. Risk of bias was determined via the Newcastle Ottawa Scale and Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. The study protocol was registered and published on the International Prospective Register of Systematic Reviews (CRD42024608378).</p><p><strong>Results: </strong>Of 905 identified studies, 16 studies met inclusion criteria, and were thus included in the meta-analysis.6,149 eyes of 3,527 patients were studied. The sensitivity in the RW group was 0.93 [95% CI, 0.83-0.98], with low heterogeneity between studies (I2 = 0.0%; p = 0.75), and the overall specificity was 0.95 [95% CI, 0.85-0.98], with heterogeneity between studies (I2 = 91.2%; p < 0.001). Certainty of evidence was graded as moderate for sensitivity and high for specificity using the GRADE approach. Regarding the TR-ROP group, the sensitivity was 0.97 [95% CI, 0.92-0.99], with low heterogeneity between studies (I2 = 0.0%; p = 0.97), and the specificity was 0.97 [95% CI, 0.91-0.99], with heterogeneity between studies (I2 = 88.2%; p < 0.001). Certainty of evidence was graded as high Post-2010 studies had greater sensitivities and specificities for RW-ROP: p < 0.001 and p = 0.77, respectively. TR-ROP sensitivity and specificity were higher in studies conducted after 2010 compared to prior: p = 0.06 and p < 0.001, respectively. Sensitivity and specificity for US vs non-US based studies were (0.83 vs 0.92, p = 0.012) and (0.97 vs 0.88, p = 0.04), respectively. Specificity for TR-ROP between US vs non-US based studies were 0.98 vs 0.95, p < 0.001, respectively.</p><p><strong>Conclusion: </strong>Remote digital fundus imaging may be an option for retinopathy of prematurity screening, particularly in low-resource areas. There was significant variability. This suggests a need for continued formal training for both photographers and graders.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-02DOI: 10.1016/j.oret.2026.03.004
Henry Bair, Sidra Zafar
{"title":"RE: Bondok et al.: Sociodemographic Reporting in Artificial Intelligence Studies of Retinal Diseases: A Critical Appraisal of The Literature (Ophthalmology Retina. 2025; 12: 1133-1139).","authors":"Henry Bair, Sidra Zafar","doi":"10.1016/j.oret.2026.03.004","DOIUrl":"https://doi.org/10.1016/j.oret.2026.03.004","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2025-10-21DOI: 10.1016/j.oret.2025.10.013
Michael Ip MD , Varun Chaudhary MD , Fanyin He PhD , Emmanuel Bouillaud MS , Yongsoo Kim MD , Franklin Igwe MPharm , Michael Singer MD
<div><h3>Objective</h3><div>To evaluate visual and anatomical outcomes of brolucizumab 6 mg versus aflibercept 2 mg in subgroups of participants with/without prior anti-VEGF treatment for diabetic macular edema in the KINGFISHER study.</div></div><div>To evaluate visual and anatomical outcomes of brolucizumab 6 mg versus aflibercept 2 mg in subgroups of participants with/without prior anti-VEGF treatment for diabetic macular edema in the KINGFISHER study.</div><div><h3>Design</h3><div>Post hoc analysis of the KINGFISHER study.</div></div><div>Post hoc analysis of the KINGFISHER study.</div><div><h3>Participants</h3><div>Of 517 participants randomized, 370 (71.6%) were treatment-naive (brolucizumab 6 mg [<em>n</em> = 251]; aflibercept 2 mg [<em>n</em> = 119]), and 147 (28.4%) prior-treated (brolucizumab 6 mg [<em>n</em> = 95]; aflibercept 2 mg [<em>n</em> = 52]) participants were included.</div></div><div>Of 517 participants randomized, 370 (71.6%) were treatment-naive (brolucizumab 6 mg [<em>n</em> = 251]; aflibercept 2 mg [<em>n</em> = 119]), and 147 (28.4%) prior-treated (brolucizumab 6 mg [<em>n</em> = 95]; aflibercept 2 mg [<em>n</em> = 52]) participants were included.</div><div><h3>Methods</h3><div>Visual and anatomical outcomes were analyzed, and descriptive statistics were provided for outcome measures.</div></div><div>Visual and anatomical outcomes were analyzed, and descriptive statistics were provided for outcome measures.</div><div><h3>Main Outcome Measures</h3><div>Assessment of the changes (least squares mean [standard error]) from baseline to week 52 in best-corrected visual acuity (BCVA) and central subfield thickness, proportion of study eyes with absence of both subretinal fluid and intraretinal fluid at week 52, proportion of participants with ≥2-step improvement from baseline to week 52 in Diabetic Retinopathy Severity Scale (DRSS) score, and incidence of intraocular inflammation (IOI)-related adverse events.</div></div><div>Assessment of the changes (least squares mean [standard error]) from baseline to week 52 in best-corrected visual acuity (BCVA) and central subfield thickness, proportion of study eyes with absence of both subretinal fluid and intraretinal fluid at week 52, proportion of participants with ≥2-step improvement from baseline to week 52 in Diabetic Retinopathy Severity Scale (DRSS) score, and incidence of intraocular inflammation (IOI)-related adverse events.</div><div><h3>Results</h3><div>The mean BCVA changes from baseline to week 52 in the prior-treated and treatment-naive subgroups were brolucizumab 6 mg (+11.0 [1.00] letters) versus aflibercept 2 mg (+8.6 [1.35] letters) and brolucizumab 6 mg (+12.6 [0.58] letters) versus aflibercept 2 mg (+12.2 [0.85] letters), respectively. Central subfield thickness reductions from baseline to week 52 in the prior-treated subgroup were brolucizumab 6 mg (–255.3 [11.27] μm) versus aflibercept 2 mg (–189.6 [15.32] μm) and in the treatment-naive subgroup were brolucizumab
{"title":"Brolucizumab for Diabetic Macular Edema in Participants with/without prior Anti-VEGF Exposure","authors":"Michael Ip MD , Varun Chaudhary MD , Fanyin He PhD , Emmanuel Bouillaud MS , Yongsoo Kim MD , Franklin Igwe MPharm , Michael Singer MD","doi":"10.1016/j.oret.2025.10.013","DOIUrl":"10.1016/j.oret.2025.10.013","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate visual and anatomical outcomes of brolucizumab 6 mg versus aflibercept 2 mg in subgroups of participants with/without prior anti-VEGF treatment for diabetic macular edema in the KINGFISHER study.</div></div><div>To evaluate visual and anatomical outcomes of brolucizumab 6 mg versus aflibercept 2 mg in subgroups of participants with/without prior anti-VEGF treatment for diabetic macular edema in the KINGFISHER study.</div><div><h3>Design</h3><div>Post hoc analysis of the KINGFISHER study.</div></div><div>Post hoc analysis of the KINGFISHER study.</div><div><h3>Participants</h3><div>Of 517 participants randomized, 370 (71.6%) were treatment-naive (brolucizumab 6 mg [<em>n</em> = 251]; aflibercept 2 mg [<em>n</em> = 119]), and 147 (28.4%) prior-treated (brolucizumab 6 mg [<em>n</em> = 95]; aflibercept 2 mg [<em>n</em> = 52]) participants were included.</div></div><div>Of 517 participants randomized, 370 (71.6%) were treatment-naive (brolucizumab 6 mg [<em>n</em> = 251]; aflibercept 2 mg [<em>n</em> = 119]), and 147 (28.4%) prior-treated (brolucizumab 6 mg [<em>n</em> = 95]; aflibercept 2 mg [<em>n</em> = 52]) participants were included.</div><div><h3>Methods</h3><div>Visual and anatomical outcomes were analyzed, and descriptive statistics were provided for outcome measures.</div></div><div>Visual and anatomical outcomes were analyzed, and descriptive statistics were provided for outcome measures.</div><div><h3>Main Outcome Measures</h3><div>Assessment of the changes (least squares mean [standard error]) from baseline to week 52 in best-corrected visual acuity (BCVA) and central subfield thickness, proportion of study eyes with absence of both subretinal fluid and intraretinal fluid at week 52, proportion of participants with ≥2-step improvement from baseline to week 52 in Diabetic Retinopathy Severity Scale (DRSS) score, and incidence of intraocular inflammation (IOI)-related adverse events.</div></div><div>Assessment of the changes (least squares mean [standard error]) from baseline to week 52 in best-corrected visual acuity (BCVA) and central subfield thickness, proportion of study eyes with absence of both subretinal fluid and intraretinal fluid at week 52, proportion of participants with ≥2-step improvement from baseline to week 52 in Diabetic Retinopathy Severity Scale (DRSS) score, and incidence of intraocular inflammation (IOI)-related adverse events.</div><div><h3>Results</h3><div>The mean BCVA changes from baseline to week 52 in the prior-treated and treatment-naive subgroups were brolucizumab 6 mg (+11.0 [1.00] letters) versus aflibercept 2 mg (+8.6 [1.35] letters) and brolucizumab 6 mg (+12.6 [0.58] letters) versus aflibercept 2 mg (+12.2 [0.85] letters), respectively. Central subfield thickness reductions from baseline to week 52 in the prior-treated subgroup were brolucizumab 6 mg (–255.3 [11.27] μm) versus aflibercept 2 mg (–189.6 [15.32] μm) and in the treatment-naive subgroup were brolucizumab ","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 4","pages":"Pages 394-402"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号